CRH PLC — Director's Dealing 2025

Mar 5, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRH PUBLIC LTD CO (CRH)
CIK: 0000849395
Period of Report: 2025-03-03

Reporting Person: San Agustin Juan Pablo (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-03	Ordinary Shares	A	32461	—	Acquired	47207	Direct
2025-03-03	Ordinary Shares	M	3698	—	Acquired	50905	Direct
2025-03-03	Ordinary Shares	F	18177	$95.2306	Disposed	32728	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-03	Deferred Share Award	$0	M	3389	Disposed		Ordinary Shares (3389)	Direct
2025-03-03	Deferred Share Award	$0	A	2100	Acquired		Ordinary Shares (2100)	Direct

Footnotes

F1: Reflects the vesting and release of awards granted in 2022 under the 2014 Performance Share Plan Rules on March 3, 2025 (including the award of 2,717 additional Ordinary Shares as dividend equivalents), pursuant to certification of the achievement of pre-established performance goals by the Compensation Committee of the Board of Directors of the Issuer (the "Compensation Committee").

F2: Reflects the vesting and release of a 2022 time-based conditional award as defined in the 2014 Deferred Share Bonus Plan (the "DSB Plan Rules"), of which, pursuant to the determination of the Compensation Committee, a total of 3,698 shares vested on March 3, 2025, including the award of 309 additional Ordinary Shares as dividend equivalents. Subject to the determination of the Compensation Committee, the remaining awards of 4,119 shares and 2,952 shares are expected to vest in March 2026 and March 2027, respectively. In accordance with the DSB Plan Rules, dividend equivalents will apply to these awards and, to the extent awarded, will be reported at the time of vesting.

F3: Mandatory sale of sufficient Ordinary Shares to cover applicable withholding tax liabilities arising in the connection with the aforementioned awards.

F4: The reported price represents the volume-weighted average price of shares sold. Sale prices for the reported transaction ranged between $92.75 and $98.705 inclusive of shares sold on the New York Stock Exchange. Full information regarding the number of Ordinary Shares sold at each separate price in the range will be provided to the SEC upon request.

F5: Reflects time-based conditional awards, as defined in the DSB Plan Rules, of which, subject to the determination of the Compensation Committee the balance will vest in March 2028. In accordance with the DSB Plan Rules, dividend equivalents will apply to the Award and, to the extent awarded, will be reported at the time of vesting.